ChemMedChem, Volume 21, Issue 7, 14 April 2026.A SAR study led to the identification of new 2‐phenylquinoline‐based derivatives that exhibit anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) activity by acting as ATP‐competitive inhibitors of nonstructural protein 13 (nsp13) helicase.
Giada Cernicchi +24 more
wiley +1 more source
Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study [PDF]
Osong Public Health and Research PerspectivesObjectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older.
Dong-Hwi Kim +7 more
doaj +1 more source
Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19
SAGE Open Medical Case Reports, 2023 COVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure.
Elizabeth DeMarco +3 more
doaj +1 more source
Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19. A prospective study [PDF]
COVID-19 represents a threat for frailty patients. This study compares molnupiravir and nirmatrelvir for fragile COVID19 patients' efficacy, safety, and cost.
Cattaruzza, Maria Sofia +6 more
core +1 more source
Structure‐ and Ligand‐Based Discovery of Novel 3‐Chymotrypsin‐Like Protease Nonpeptidomimetic Hits
ChemMedChem, Volume 21, Issue 7, 14 April 2026.A multistep virtual screening cascade, integrating shape‐based, ensemble docking, and quantitative structure–activity relationship (QSAR) models, was employed to screen 1.5 million compounds. This funnel identified a novel 3‐chymotrypsin‐like protease (3CLpro) inhibitor, LabMol‐499, which was experimentally validated using a Förster Resonance Energy ...
Sabrina Silva‐Mendonça +14 more
wiley +1 more source
Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions
Infectious Diseases and TherapyIntroduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of ...
Abby E. Rudolph +5 more
doaj +1 more source
Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial [PDF]
Background: Molnupiravir and nirmatrelvir-ritonavir (Paxlovid) are oral antivirals that have been proposed as treatments for patients admitted to hospital with COVID-19.
Amuasi, John +39 more
core +2 more sources
Health Science Reports, Volume 9, Issue 4, April 2026.ABSTRACT Background and Aims Despite evidence of effectiveness, oral antivirals for COVID‐19 are underused, with significant variation across populations. This study examines COVID‐19 treatment awareness, knowledge, access, trusted sources, and willingness to use among diverse essential workers in Tennessee during May 18, 2023–June 1, 2024.
Jenae Sanders +12 more
wiley +1 more source
Infection and Drug Resistance, 2023 Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X +8 more
doaj